Main Mechanisms of Tigecycline Resistance
Tigecycline, a glycylcycline antibiotic, targets the bacterial ribosome to inhibit protein synthesis. Resistance emerges primarily through efflux pumps that expel the drug from the cell before it reaches its target. In Enterobacteriaceae like E. coli and Klebsiella pneumoniae, the most common mechanism involves overexpression of the AcrAB-TolC efflux pump, driven by mutations or upregulation in regulators such as MarR, SoxS, or RamR. These pumps reduce intracellular tigecycline concentrations below lethal levels.[1][2]
Another key pathway is ribosomal protection via Tet(X) enzymes, originally from Bacteroides but now plasmid-mediated in Gram-negatives. Tet(X) modifies tigecycline, preventing ribosome binding, and has spread via mobile genetic elements like IncQ plasmids.[3]
In Gram-positives like Staphylococcus aureus, resistance often stems from mutations in ribosomal proteins (e.g., RpmC or RplC) or efflux via NorA pumps, though less frequently than in Gram-negatives.[4]
How Resistance Spreads in Clinical Settings
Resistance develops stepwise under selective pressure from tigecycline use, especially in hospitals treating multidrug-resistant infections. Low-dose therapy or suboptimal pharmacokinetics can sublethally expose bacteria, favoring mutants. Horizontal gene transfer accelerates this: Tet(X)-carrying plasmids conjugate between species, while efflux regulators mutate spontaneously at rates of 10^-7 to 10^-9 per cell division.[2][5]
Outbreaks link to ventilated patients or ICU settings, where Acinetobacter baumannii gains resistance via AdeABC efflux overexpression.[6]
Which Bacteria Show Rising Tigecycline Resistance?
Resistance rates vary:
- Carbapenem-resistant Enterobacteriaceae (CRE): Up to 10-20% in China and India, driven by Tet(X4) variants.[3]
- A. baumannii: 5-15% globally, often efflux-mediated.[6]
- Pseudomonas aeruginosa: Rare intrinsic resistance via MexXY-OprM pumps.[4]
Surveillance data from SENTRY (2014-2019) show MIC90 creeping from 2 mg/L to 4 mg/L in Enterobacterales.[7]
Factors Accelerating Resistance Development
High tigecycline use in agriculture (as a feed additive in some regions) selects for Tet(X) in animal gut microbiomes, spilling into humans via food chains.[3] Combination therapy delays onset but doesn't eliminate risk—e.g., tigecycline plus colistin still sees efflux emergence in A. baumannii.[6]
Poor lung penetration contributes, as tigecycline underdoses pneumonia cases, fostering resistance.[1]
Can We Predict or Prevent Tigecycline Resistance?
PK/PD modeling predicts resistance if AUC/MIC ratios fall below 100. Prevention relies on stewardship: short courses, high doses (100 mg BID loading), and alternatives like eravacycline for high-risk cases. No tigecycline-specific vaccines exist, but phage therapy trials target resistant strains.[5][8]
[1] PubMed: Tigecycline resistance mechanisms
[2] Nature Reviews Microbiology: Efflux in Gram-negatives
[3] Lancet Infectious Diseases: Tet(X) plasmid spread
[4] Clinical Microbiology Reviews: Glycylcycline resistance
[5] Antimicrobial Agents and Chemotherapy: PK/PD tigecycline
[6] Journal of Antimicrobial Chemotherapy: Acinetobacter resistance
[7] SENTRY Antimicrobial Surveillance Program
[8] ClinicalTrials.gov: Phage therapy for MDR infections